COPENHAGEN, March 7 (Reuters) - Lundbeck A/S : * Says Otsuka and Lundbeck expand their existing collaboration * Says collaboration to include promotion of Abilify swallowable tablets, oral
solution, orally-disintegrating tablets and the intramuscular rapid
injectable in 14 European countries. * A once-monthly injectable form of Abilify, will be co-promoted by Otsuka and Lundbeck in the U.S. and will start becoming available there from March 18. * The drug was approved for use in schizophrenia by the U.S. FDA (Food and Drug Administration) on February 28.